Oral-Absorption-Enhancing Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Oral-Absorption-Enhancing Drug-Delivery Technology
The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.


Pharmaceutical Technology
Volume 35, pp. s12-s14

Conclusion

The GIPET technology is an advanced-stage permeation enhancement oral drug-delivery platform based on enhancers that have been studied in cells, tissues, rodents, dogs, and humans to demonstrate their ability to promote drug absorption, safety, reversibility, and mechanism of action. The technology is suitable for a wide range of different molecule types as evidenced by the preclinical and clinical studies showing enhanced intestinal absorption.

Acknowledgments

The authors thank David Brayden, professor at the University College Dublin in Ireland for critical reading of the manuscript. The authors also want to acknowledge that the work of Edwin Walsh is funded by an Irish Research Council for Science, Engineering and Technology (IRCSET)–Industry Partnership between the Irish Government and Merrion Pharmaceuticals.

Edwin G. Walsh, BSc, is a PhD student at the School of Veterinary Medicine and Conway Institute, University College Dublin, in Dublin, Ireland. Alan P. Cullen, MSc, is preclinical development manager, John S. Fox, PhD, MBA, is chief development officer, and Thomas W. Leonard*, RPh, PhD, is vice-president and chief scientific officer, all at Merrion Pharmaceuticals, 219 Racine Drive, Suite D, Wilmington, NC 28403, tel. 910.799.1847, fax 910.395,1843,
.

References

1. E. Windsor and G.E. Cronheim, Nature 190 (4772), 263–264 (1961).

2. M. Hayashi, M. Tomita, and A. Awazu, Adv. Drug Deliv. Rev. 28 (2), 191–204 (1997).

3. T. Lindmark, T. Nikkila, and P. Artursson, J. Pharmacol. Exp. Ther. 275 (2), 958–964 (1995).

4. H. Huang and R.E. Verall, J. Solution Chem. 26 (2) 135–162 (1997).

5. Y. Lo and J. Huanh, Biochem. Pharmacol. 59 (6), 665–672 (2000).

6. JECFA, 29th Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series No. 733 (1986).

7. L. Blomquist, Gastroenterol. 32 (8), 805–812 (1997).

8. A.J. Ryan, R-T. Chang, and C.V. Gisolfi, Med. & Sci. in Sports & Exerc. 28 (6), 698–705 (1996).

9. T.T. Kararli, Biopharm. Drug Dispos. 16 (5), 351–380 (1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here